{"id":"ras-2410","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"RAS 2410 works by blocking the activity of the RAS protein, which is involved in cell growth and division. This can help to slow or stop the growth of cancer cells. By inhibiting the RAS pathway, RAS 2410 may help to reduce the size of tumors and slow disease progression.","oneSentence":"RAS 2410 is a selective inhibitor of the RAS pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:01.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT04525729","phase":"PHASE4","title":"Rituximab and RASi in Patients with IgAN","status":"COMPLETED","sponsor":"Nan Chen,MD","startDate":"2020-07-01","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT02953301","phase":"PHASE2","title":"Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)","status":"COMPLETED","sponsor":"4SC AG","startDate":"2016-11","conditions":"Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous","enrollment":201},{"nctId":"NCT04955340","phase":"PHASE1","title":"A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat","status":"COMPLETED","sponsor":"4SC AG","startDate":"2021-10-12","conditions":"Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome","enrollment":5},{"nctId":"NCT02400788","phase":"PHASE1, PHASE2","title":"Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Yakult Honsha Co., LTD","startDate":"2013-04","conditions":"Hepatocellular Carcinoma","enrollment":179},{"nctId":"NCT01277406","phase":"PHASE1, PHASE2","title":"4SC-201 (Resminostat) in Advanced Colorectal Carcinoma","status":"COMPLETED","sponsor":"4SC AG","startDate":"2011-01","conditions":"Advanced Colorectal Carcinoma","enrollment":17},{"nctId":"NCT01037478","phase":"PHASE2","title":"Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"4SC AG","startDate":"2009-12","conditions":"Hodgkin's Lymphoma","enrollment":37},{"nctId":"NCT00943449","phase":"PHASE2","title":"4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"4SC AG","startDate":"2009-07","conditions":"Hepatocellular Carcinoma","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["No specific restrictions"],"phase":"marketed","status":"active","brandName":"RAS 2410","genericName":"RAS 2410","companyName":"Nan Chen,MD","companyId":"nan-chen-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RAS 2410 is a selective inhibitor of the RAS pathway. Used for Non-small cell lung cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}